Furuta Eiji, Pai Sudha K, Zhan Rui, Bandyopadhyay Sucharita, Watabe Misako, Mo Yin-Yuan, Hirota Shigeru, Hosobe Sadahiro, Tsukada Taisei, Miura Kunio, Kamada Shuichi, Saito Ken, Iiizumi Megumi, Liu Wen, Ericsson Johan, Watabe Kounosuke
Department of Medical Microbiology, Immunology, and Cell Biology, Southern Illinois University School of Medicine, Springfield, Illinois 62794-9626, USA.
Cancer Res. 2008 Feb 15;68(4):1003-11. doi: 10.1158/0008-5472.CAN-07-2489.
The fatty acid synthase (FAS) gene is significantly up-regulated in various types of cancers, and blocking the FAS expression results in apoptosis of tumor cells. Therefore, FAS is considered to be an attractive target for anticancer therapy. However, the molecular mechanism by which the FAS gene is up-regulated in tumor cells is poorly understood. We found that FAS was significantly up-regulated by hypoxia, which was also accompanied by reactive oxygen species (ROS) generation in human breast cancer cell lines. The FAS expression was also activated by H(2)O(2), whereas N-acetyl-L-cystein, a ROS inhibitor, suppressed the expression. We also found that the hypoxia significantly up-regulated sterol regulatory-element binding protein (SREBP)-1, the major transcriptional regulator of the FAS gene, via phosphorylation of Akt followed by activation of hypoxia-inducible factor 1 (HIF1). Moreover, our results of reporter assay and chromatin immunoprecipitation analysis indicate that SREBP-1 strongly bound to the SREBP binding site/E-box sequence on the FAS promoter under hypoxia. In our xenograft mouse model, FAS was strongly expressed in the hypoxic regions of the tumor. In addition, our results of immunohistochemical analysis for human breast tumor specimens indicate that the expressions of both FAS and SREBP-1 were colocalized with hypoxic regions in the tumors. Furthermore, we found that hypoxia-induced chemoresistance to cyclophosphamide was partially blocked by a combination of FAS inhibitor and cyclophosphamide. Taken together, our results indicate that FAS gene is up-regulated by hypoxia via activation of the Akt and HIF1 followed by the induction of the SREBP-1 gene, and that hypoxia-induced chemoresistance is partly due to the up-regulation of FAS.
脂肪酸合酶(FAS)基因在多种类型的癌症中显著上调,阻断FAS表达会导致肿瘤细胞凋亡。因此,FAS被认为是抗癌治疗的一个有吸引力的靶点。然而,FAS基因在肿瘤细胞中上调的分子机制尚不清楚。我们发现FAS在缺氧条件下显著上调,同时人乳腺癌细胞系中也会产生活性氧(ROS)。FAS表达也被过氧化氢激活,而ROS抑制剂N - 乙酰 - L - 半胱氨酸可抑制其表达。我们还发现缺氧通过Akt磷酸化随后激活缺氧诱导因子1(HIF1),显著上调FAS基因的主要转录调节因子固醇调节元件结合蛋白(SREBP)-1。此外,我们的报告基因检测和染色质免疫沉淀分析结果表明,在缺氧条件下SREBP -1与FAS启动子上的SREBP结合位点/E -盒序列强烈结合。在我们的异种移植小鼠模型中,FAS在肿瘤的缺氧区域强烈表达。此外,我们对人乳腺肿瘤标本的免疫组织化学分析结果表明,FAS和SREBP -1的表达均与肿瘤中的缺氧区域共定位。此外,我们发现FAS抑制剂与环磷酰胺联合使用可部分阻断缺氧诱导的对环磷酰胺的化疗耐药性。综上所述,我们的结果表明,缺氧通过激活Akt和HIF1随后诱导SREBP -1基因来上调FAS基因,并且缺氧诱导的化疗耐药性部分归因于FAS的上调。